DOCSLIB.ORG

Cardiovascular Toxins Kerns

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Cardiovascular Toxins Kerns 8/11/14 ACMT Board Review 2014: Cardiovascular Toxins Russ Kerns, MD, FACMT Carolinas Medical Center Charlotte, NC Objectives: 2.1.6 Drugs that affect the cardiovascular system n 2.1.6.1 Antidysrhythmics n 2.1.6.1.1 calcium channel blockers n 2.1.6.1.2 cardiac glycosides n 2.1.6.1.3 potassium channel blockers n 2.1.6.1.4 sodium channel blockers n 2.1.6.2 Antihypertensives n 2.1.6.2.1 Angiotensin modulators n 2.1.6.2.2 β-adrenergic receptor antagonists n 2.1.6.2.3 central α-agonists n 2.1.6.2.4 diuretics n 2.1.6.2.5 vasodilators n 2.1.6.3 Inotropes n Provide key example toxins and visual stimuli Key Principles n Cardiac action potential n Sodium channels n Potassium channels n Na+-K+ ATPase n Electromechanical coupling n Calcium channels n Modulators n Β-adrenergic receptors 1 8/11/14 Cardiac Action Potential n Phase 0 n electrical stimulus n sodium influx via fast Na+ channels n ↑ resting membrane potential n depolarization Cardiac Action Potential n Phase 1 n Repolarization of membrane begins n Na+ channels close n Potassium efflux (outward rectifying current) Cardiac Action Potential n Phase 2 n plateau phase n calcium influx n potassium efflux 2 8/11/14 Cardiac Action Potential n Phase 3 n repolarization n Calcium channels close n Potassium efflux continues Cardiac Action Potential n Phase 4 n Resting state Sodium Channel 3 8/11/14 Na+ Channel Structure n Found in neurons, glial cells & myocytes n 9 subtypes n Tetrameric protein n Transmembrane n SCN gene n SCN5 – Brugada Syndrome n Voltage-gated (myocardial) n Ligand-gated (nicotinic) Na+ Channel Function n Resting (Closed) n Open n Inactivated (Closed) n Refractory to opening Na+ Channel Modulation n Agonists – channel openers n Aconitine (Monk’s Hood) n Batrachotoxin (Poison Dart Frog) n Grayanotoxin (Azalea and Rhododendron sp) n some are antagonists n Veratridine (Veratrum sp – False Hellebore) n Zygacine (Zygadenus sp – Death Camus) 4 8/11/14 Na+ Channel Agonists n Clinical consequences n Ventricular dysrhythmias n Bradycardia n Treatment n Na+ channel antagonists n Cardioversion/defibrillation Na+ Channel Modulation: Antagonists n Antidysrhythmics 2.1.6.1.4 n Ia Antidysrhythmics n Procainamide, quinidine, disopyramide n Ib Antidysrhythmics n Lidocaine, mexilitine, phenytoin n Ic Antidysrhythmics n Encainide, flecainide, propafenone Na+ Channel Modulation: Antagonists n Other sodium channel blocking drugs n Analgesics: propoxyphene n Anticonvulsants: carbamazepine n Antidepressants: cyclics, bupropion, venlafaxine n Antimalarials: quinine, chloroquine, hydroxychloroquine n Class II antidysrhythmics: propranolol, acebutolol n Class III antidysrhythmics: amiodarone n Local anesthetics n Phenothiazines: diphenhydramine, thioridazine n Others: cocaine, propylene glycol 5 8/11/14 Na+ Channel Modulation: Antagonists n Natural toxins n Grayanotoxins n Some are agonists n Taxine (Taxus sp – Yew) X Widened QRS 6 8/11/14 Wide QRS: ECG as Prognostic Tool for Cyclic Antidepressant OD n Reflects activity at the sodium channel n Limb lead QRS duration n > 100 ms risk of seizures n > 160 ms risk of ventricular dysrhythmias Boehnert. NEJM 1985;313:474-9 Na+ Channel Antagonism: Rate-dependent baseline 2:50 min QRS – 140 ms; BP - 145/78 mmHg QRS – 160 ms; BP - 151/68 mmHg 5:50 min 7:50 min QRS – 180 ms; BP -164/65 mmHg QRS – 220 ms; BP - 0 mmHg Terminal Axis Deviation 7 mm R’ 7 8/11/14 Sodium Channel Blockade: Rightward Terminal Axis normal right axis deviation n R’ wave in aVR > 3 mm n R’:S ratio in aVR > 0.7 Liebelt et al. Ann Emerg Med 1995;26:195-201 Brugada ECG Pattern u Terminal right axis deviation u Coved (saddle) ST segment elevation precordium Littmann et al. Am Heart J 2003;145:768-78; Beberta et al. Clin Toxicol 2007;45:186-8 Sodium Channel Blockade: Consequences ventricular tachycardia torsades de pointes n Treatment n Sodium bicarbonate n Lidocaine (?) n Cardioversion/defibrillation 8 8/11/14 Sodium Channel Blockade: Hypertonic Sodium Bicarbonate n Sodium ion n Reverses competative Na+ channel antagonism n Alkalinization n Increased drug-protein binding (↓ free drug) n decreased drug binding at the Na+ channel Sodium Channel Blockade Treatment: Why Lidocaine? n Class 1a n Blocks in resting state n Recovery: 1-10 ms n Class 1b n Blocks in inactive state n Recovery: <1 ms n Class 1c n Blocks in inactive state n Recovery: >10 ms Lidocaine is “fast on and fast off” so there is a greater chance of channel opening Antidysrhythmic Factoids n Class Ia: procainamide n Metabolism via acetylation n NAPA: K+ channel blockade n Polymorphic metabolism n Acute OD: seizures, dysrhythmias n Chronic use: SLE, myopathy, thrombocytopenia, agranulocytosis n False positive amphetamine on enzyme- based urine drug screens 9 8/11/14 Antidysrhythmic Factoids n Class Ia: quinidine n Torsades de pointes (K+ channel blockade) n Qunidine syncopy n Cinchonism (abdominal pain, tinnitus, AMS) n d-isomer of quinine n Hypoglycemia n dis-inhibited pancreatic insulin release due to K+ channel blockade n Class 1a: disopyramide n Anticholinergic n Hypoglycemia (pancreatic K+ blockade) Antidysrhythmic Factoids n Class Ib: lidocaine n Acute toxicity: CNS and dysrhythmias n Lidocaine wraps and liposuction n Metabolism n Hepatic CYP3A4 (saturable/drug interactions) n Active metabolite (MEGX) n Adverse drug event risks: n Advanced age n Hepatic insufficiency n Prolonged infusion (>3 mg/min for 24-72 hr) Antidysrhythmic Factoids n Class Ib: tocainide n ADRs limit clinical use n Rash, heptatoxicity, blood dyscrasias n Class 1b: mexiletine n CYP2D6 interactions n False positive amphetamine on enzyme-based urine drug screens 10 8/11/14 Antidysrhythmic Factoids n Class Ic: flecainide n Procainamide derivative n Prolonged PR and QRS duration with minimal QT prolongation n Negative inotrope n Class 1c: propafenone n Also β-blocker and calcium channel antagonist n Bradycardia, wide QRS, negative inotropy Ca2+ Channels n L-type n N-type (neuronal) n P-type (Purkinje) n T-type (muscular) L-type Ca2+ Channel n Four proteins n Span cell membranes n Regulates calcium entry n Closed in resting state n Require activation to open n Channel location determines the functional result of calcium entry 11 8/11/14 L-type Ca2+ Channel endocrine non-vascular smooth muscle Ca2+ Channel Activation - Myocardial n Ca2+- mediated Ca2+ - release n Result n éHR n écontractility n Modulators n Catecholamines n G protein n cAMP n protein kinase Ca2+ Channel Activation - Vascular n Result n vasoconstriction n Maintenance of BP n Modulators n α1 stimulation n β2 stimulation n angiotensin n endothelin 12 8/11/14 Ca2+ Channel Antagonism Consequences: X Hypotension Bradycardia Poor cardiac output Cardiogenic Shock Ca2+ Channel Agonist n Levosimendan n Directly opens Ca2+ channel n Heart failure treatment n Experimental treatment of CCB toxicity n No human overdose Ca2+ Channel Antagonism n Class IV drugs n Nifedipine (dihydropyridine) n Diltiazem (benzothiazepine) n Verapamil (phenylalkylamine) n Bepridil (diarylaminopropylamine) n Cyclic antidepressants n Class 1c agent Propafenone 13 8/11/14 Calcium Channel Blocker Factoids n Class IV observations n Pharmacokinetics n Hepatic metabolism n Highly protein bound n Drug interactions X n CYP3A4 and P-glycoprotein inhibitors n Digoxin, theophylline, OTHERS!!! n Acute toxicity n Bradycardia, hypotension, decreased contractility n Diabetogenic state Class IV Toxicity: Treatment n Decontamination n Charcoal for sustained release formulations n Pharmacotherapy n Calcium salts n Glucagon n High-dose insulin n Intravenous lipid emulsion (too recent for exam) n Phosphodiesterase inhibitors n Vasopressors n Technological therapy – novel (except pacing) n Aortic balloon pump, ECMO, MARS, Pacing, LVADs Potassium Channels 14 8/11/14 K+ Channel Structure n Tetrameric protein in the cell membrane n Central pore through which K+ flows n Normally closed n Opening leads to K+ efflux from the cell K+ Channel Function n Inhibition of cell function n Acts to prevent overuse of the cell n Opening stimuli n êintracellular energy molecules (ATP) n éintracellular Na+ n éintracellular Ca2+ Normal Function: Myocardial K+ Channel 2+ Ca + mV Na+ - mV 15 8/11/14 Normal Function: Myocardial K+ Channel n Effective Refractory Period n Depolarization not possible n Relative Refractory Period n Depolarization possible with sufficient electrical stimulus ERP RRP K+ Channel Modulation n K+ channel inhibition n Prolongs action potential (phase 3) n Equalizes refractoriness of ischemic and non- ischemic tissues without slowing conduction n ↑RRP allows for dysrhythmias (TdP) Na+ X Prolonged QTc / TdP n Antidysrhythmic n Class I (procainamide, quinidine and quinine) n Class II (sotalol) n Class III (amiodarone, bretylium, dofetilide, ibutilide) n Antidepressants n Serotonin agonists n Antihistamine n terfenadine, astemizole n Antipsychotic n haloperidol - butyrophenone n thioridazine - phenothiazine n sertindole - atypical 16 8/11/14 Prolonged QTc / TdP n GI agents n cisapride n Metabolic n hypokalemia (diuretics) n hypomagnesemia (diuretics) n Metals n arsenic www.torsades.org Antidysrhythmic Factoids n Class III: Amiodarone n Pharmacology n Structurally similar to T3 and is 40% iodine n Class Ic, II, IV activity n Competes for p-glycoprotein n ↑ digoxin and cyclosporine concentrations n ↑ warfarin anticoagulation 17 8/11/14 Antidysrhythmic Factoids n Class III: Amiodarone n ADRs with chronic therapy n Pneumonitis n dose dependent >400 mg/day n Oxygen sensitive n Hypo- or hyperthyroidism n Hepatic transaminitis n Corneal deposits n Sun-sensitive
Load more

Recommended publications
  • Drug Interactions of Some Commonly Used Drugs in Dermatology
    Table Drug interactions of some commonly used drugs in dermatology M. J. Cyriac Department of Dermatology and Venereology, Medical College, Kottayam, India. Address for correspondence: Dr. M. J. Cyriac, Professor and Head, Department of Dermatology and Venereology, Medical College, Kottayam, India. E-mail: [email protected] Drug interactions leading to serious adverse effects are alternative medicines or food should also be borne in to be cautiously watched for when multiple drugs are mind.2 Increased risk of drug induced toxicity or used simultaneously.1 It is important for the physician therapeutic failure can occur when a new drug is added to be aware of these interactions. Although in many to a treatment regimen. It is impossible to remember instances the adverse interaction does not reach a all possible drug interactions. A ready to refer checklist magnitude of recognizable clinical expression, rarely is useful as a handy reference. it can result in a serious adverse outcome. Some of the commonly used drugs in dermatology and Adverse drug interactions may lead to increased their interactions, resultant clinical effect and possible toxicity, decreased efficacy or both. The possibility of underlying mechanisms are given in Table 1. Table 2 lists interaction with non-prescription drugs, herbal or the drugs with their relative risk for inducing interactions. Table 1: Drug interactions of some commonly used drugs Drug Interacting drug Adverse effect Remarks Erythromycin/Clarithromycin Theophylline Theophylline toxicity Precipitates
    [Show full text]
  • DRI® Digoxin Assay
    DRI® Digoxin Assay For In Vitro Diagnostic Use 1669 (25 mL, 8 mL Kit) 1669-A (25 mL, 8 mL Kit) Intended Use Reagent Preparation and Storage The DRI® Digoxin Assay is intended for the quantitative determination of digoxin in human The reagents are ready for use. No reagent preparation is required. All assay components, serum or plasma. when stored properly at 2-8°C, are stable until the expiration date indicated on the label. Summary and Explanation of the Test Specimen Collection and Handling Digitalis is known to have the ability to increase the force and velocity of myocardial Pharmacokinetic factors, such as dosage form, mode of administration, concomitant drug therapy contraction.1 Digoxin is one of the most commonly used forms of digitalis in the treatment as well as the patient’s clinical condition may influence the correct time of sample collection.2,3 For of congestive heart failure and arrhythmia such as atrial fibrillation and atrial flutter. The reliable interpretation of results, a serum specimen should be collected 6 to 8 hours following therapeutic range of digoxin is narrow. Futhermore, individual differences in drug absorption, the last oral dose of digoxin. Either serum or heparin and EDTA treated plasma samples can distribution, metabolism, and excretion as well as factors such as concurrent use of other drugs be used with the assay. Samples may be stored refrigerated at 2-8°C for up to 7 days or frozen and illness can also alter the serum concentration in response to a given dosage. Monitoring (-20°C) for up to 6 months.
    [Show full text]
  • Report on the National Seminar on Radioimmunoassays Radiation Medicine Centre, B.A.R.C
    REPORT ON THE NATIONAL SEMINAR ON RADIOIMMUNOASSAYS JANUARY 16-20, 1978 RADIATION MEDICINE CENTRE, B.A.R.C. DEPARTMENT OF ATOMIC ENERGY AND WORLD HEALTH ORGANISATION REPORT ON THE NATIONAL SEMINAR ON RADIOIMMUNOASSAYS JANUARY 16—20, 1978 RADIATION MEDICINE CENTRE, BARC TATA MEMORIAL HOSPITAL ANNEXE JERBAI WADIA ROAD, PAREL BOMBAY 400 012 ORGANISED UNDER THE AUSPICES OF THE DEPARTMENT OF ATOMIC ENERGY & WORLD HEALTH ORGANISATION CONTENTS Page Preface .. .. .. .. .. .. .. 3 Administrative Responsibilities .. .. .. .. 6 List of Participants 7 Programme .. .. .. .. .. .. .. 11 Basic Requirements of RIA in India .. .. .. 14 a. Radioisotopes for RIA's .. .. .. .. .. 15 b. Kits for RIA 17 c. Availability of Antibodies 19 d. National Pituitary Agency .. .. .. .. 20 e. Well-counter for RIA 21 f. Radiation Protection Aspects of RIA 23 Review of Discussion following the Session .. .. 26 State of Art of RIA's in India 28 Trigger Sessions 36 a. Quality Control of RIA's 37 b. Usefulness and limitations of RIA's in clinical diagnosis 39 c. RIA's in tropical diseases •. .. .. .. .. 42 d. Centralised assay services .. .. .. .. 44 Recommendations and Guidelines .. .. .. .. 46 Backword 51 Bibliography . .. .. .. .. .. .. 53 PREFACE This National Seminar on Radioimmunoassays was the second National Seminar jointly sponsored by Department of Atomic Energy and World Health Organisation and organised at Radiation Medicine Centre. The first one on 'Nuclear Medicine in India' was held in December 1976. The present Seminar on Radioimmunoassays was distinguished by the participation of Dr. Rosalyn Yalow, Nobel Laureate in Medicine for 1977. She, along with Dr. Solomon A. Berson, discovered the technique of Radioimmunoassay and nurtured it through the early years with hard and meticulous work to establish its usefulness in medical science.
    [Show full text]
  • Digoxin SAFETY DATA SHEET Section 2. Hazards Identification
    SAFETY DATA SHEET Page: 1 of 6 Digoxin Revision: 08/24/2017 according to Regulation (EC) No. 1907/2006 as amended by (EC) No. 1272/2008 Section 1. Identification of the Substance/Mixture and of the Company/Undertaking 1.1 Product Code: 22266 Product Name: Digoxin Synonyms: (3.beta.,5.beta.,12.beta.)-3-[(O-2,6-dideoxy-.beta.-D-ribo-hexopyranosyl-(1->4)-O-2,6-dideoxy-.b eta.-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-.beta.-D-ribo-hexopyranosyl)oxy]-12,14-dihydroxy- card-20(22)-enolide; NSC 95100; 1.2 Relevant identified uses of the substance or mixture and uses advised against: Relevant identified uses: For research use only, not for human or veterinary use. 1.3 Details of the Supplier of the Safety Data Sheet: Company Name: Cayman Chemical Company 1180 E. Ellsworth Rd. Ann Arbor, MI 48108 Web site address: www.caymanchem.com Information: Cayman Chemical Company +1 (734)971-3335 1.4 Emergency telephone number: Emergency Contact: CHEMTREC Within USA and Canada: +1 (800)424-9300 CHEMTREC Outside USA and Canada: +1 (703)527-3887 Section 2. Hazards Identification 2.1 Classification of the Substance or Mixture: Acute Toxicity: Inhalation, Category 3 Acute Toxicity: Oral, Category 2 Serious Eye Damage/Eye Irritation, Category 2 Specific Target Organ Toxicity (repeated exposure), Category 2 Aquatic Toxicity (Acute), Category 1 2.2 Label Elements: GHS Signal Word: Danger GHS Hazard Phrases: H300: Fatal if swallowed. H319: Causes serious eye irritation. H331: Toxic if inhaled. H373: May cause damage to {organs} through prolonged or repeated exposure. H400: Very toxic to aquatic life.
    [Show full text]
  • Grayanotoxin Poisoning in Humans from Honey Consumption HELENA COLOMA DÍEZ AUTONOMOUS UNIVERSITY of BARCELONA
    Grayanotoxin Poisoning in Humans from Honey Consumption HELENA COLOMA DÍEZ AUTONOMOUS UNIVERSITY OF BARCELONA Objectives Structure, Types and Isolation of GTX The main objective of this bibliographic research is compiling and announcing information Grayanotoxins are non-volatile diterpenes, a about grayanotoxin-containing honey and the toxic effects derived from its ingestion. This polyhidroxylated cyclic hydrocarbon with a 5/7/6/5 ring substance is believed to have medicinal properties, and the current increment of use of structure that does not contain nitrogen, as seen on figure 2. There are 25 known isoforms of grayanotoxins, natural products as dietetic complements with this finality may cause a rising in the number GTX-I and GTX-III being the most common and of intoxication cases. So it is important learning to recognise the clinical signs it causes and abundant ones, followed by GTX-II. their treatment, apart from finding out if it may have medicinal applications. TheGTXcanbeisolatedbytypicalextraction procedures for naturally occurring terpenes, such as paper electrophoresis, thin-layer chromatography (TLC), and gas chromatography (GC). They require derivatization before GC analysis due to the Introduction compound’s instability on heating and having low vapor pressure. Other identification techniques are based on The poisoning caused by grayanotoxin-containing honey, called “mad honey”, is known from infrared (IR), nuclear magnetic resonance (NMR), and antiquity. This toxic honey has been used for different purposes, such as biological weapon mass spectrometry (MS). or therapeutical product. Figure 2. Structure formulas (left pannel) and 3D The origin of this toxin relays in some plants of the Rhododendron genus, widespread all representations (right pannel) of GTX-I, II and III.
    [Show full text]
  • Digoxin Toxicity 1
    Chronic Digoxin Toxicity Reviewers: Shawn M. Varney, Authors: Matthew Riddle, MD, Mel Otten, MD MD Target Audience: Emergency Medicine Residents (junior and senior level postgraduate learners), Medical Students Primary Learning Objectives: 1. Recognize signs and symptoms of digoxin toxicity 2. Order appropriate diagnostic studies for evaluation of digoxin toxicity 3. Appropriately interpret ECG 4. Administer digoxin-specific antibody fragments (DSFab) 5. Recognize acute kidney injury as a precipitating factor of toxicity, and treat acute kidney injury appropriately 6. Select an appropriate disposition for patient with digoxin toxicity Secondary Learning Objectives: detailed technical/behavioral goals, didactic points 1. Develop independent differential diagnosis in setting of leading information from the nurse 2. Describe the mechanism of digoxin toxicity and treatment, DSFab 3. Use appropriate dosing strategy for DSFab administration Critical actions checklist: 1. Order a basic metabolic panel 2. Order a digoxin level 3. Obtain ECG 4. Provide volume resuscitation for acute kidney injury 5. Administer digoxin antibody fragments 6. Consult Poison Center/Toxicologist 7. Admit to the MICU Environment: Emergency Department treatment area 1. Room Set Up – ED critical care area a. Manikin Set Up – Mid or high fidelity simulator b. Props – Standard ED equipment 2. Distractors – ED noise, alarming monitor For Examiner Only CASE SUMMARY SYNOPSIS OF HISTORY/ Scenario Background The setting is an urban emergency department. The patient is a 63-year-old male with a history of atrial fibrillation, HTN, and CHF brought to the emergency department by EMS for nausea and vomiting for the past four days and confusion that began shortly before arrival. PMHx: atrial fibrillation, HTN, and CHF PSHx: None Medications: ASA 81 mg once daily, Digoxin 250 mcg once daily, Amlodipine 10 mg once daily, Lasix 20 mg twice daily, warfarin 5 mg once daily Allergies: NKDA SocHx: smokes ½ ppd for 40 years.
    [Show full text]
  • Question of the Day Archives: Monday, December 5, 2016 Question: Calcium Oxalate Is a Widespread Toxin Found in Many Species of Plants
    Question Of the Day Archives: Monday, December 5, 2016 Question: Calcium oxalate is a widespread toxin found in many species of plants. What is the needle shaped crystal containing calcium oxalate called and what is the compilation of these structures known as? Answer: The needle shaped plant-based crystals containing calcium oxalate are known as raphides. A compilation of raphides forms the structure known as an idioblast. (Lim CS et al. Atlas of select poisonous plants and mushrooms. 2016 Disease-a-Month 62(3):37-66) Friday, December 2, 2016 Question: Which oral chelating agent has been reported to cause transient increases in plasma ALT activity in some patients as well as rare instances of mucocutaneous skin reactions? Answer: Orally administered dimercaptosuccinic acid (DMSA) has been reported to cause transient increases in ALT activity as well as rare instances of mucocutaneous skin reactions. (Bradberry S et al. Use of oral dimercaptosuccinic acid (succimer) in adult patients with inorganic lead poisoning. 2009 Q J Med 102:721-732) Thursday, December 1, 2016 Question: What is Clioquinol and why was it withdrawn from the market during the 1970s? Answer: According to the cited reference, “Between the 1950s and 1970s Clioquinol was used to treat and prevent intestinal parasitic disease [intestinal amebiasis].” “In the early 1970s Clioquinol was withdrawn from the market as an oral agent due to an association with sub-acute myelo-optic neuropathy (SMON) in Japanese patients. SMON is a syndrome that involves sensory and motor disturbances in the lower limbs as well as visual changes that are due to symmetrical demyelination of the lateral and posterior funiculi of the spinal cord, optic nerve, and peripheral nerves.
    [Show full text]
  • Top Ten Potential Drug Interactions in Small Animal Medicine EJCAP 26(34 Autumn 2016 P 9
    Top Ten Potential Drug Interactions in Small Animal Medicine EJCAP 26(34 Autumn 2016 P 9 Fecava lecture* Top Ten Potential Drug Interactions in Small Animal Medicine Jennifer M. Reinhart, Lauren A. Trepanier1 SUMMARY Today, comorbidities are increasingly diagnosed in veterinary patients and multiple drug combinations are common. However, as the number of administered drugs increases, so too does the risk for adverse drug interactions. Much of what is known about drug-drug interactions is taken from the human literature, but a growing body of work in veterinary medicine also exists. The purpose of this review is to summarize the current knowledge of potential drug interactions in humans and dogs for ten ‘at risk’ drugs used in small animal medicine: cimetidine, sucralfate, ketoconazole, fluoroquinolone antibiotics, omeprazole, phenobarbital, clomipramine, furosemide, metoclopramide, and cyclosporine. Increased awareness of these potential drug interactions will enhance therapeutic decision-making and improve the level of care for veterinary patients. Key words: drug-drug interaction, drug metabolism, adverse drug reaction, polypharmacy *This paper is based on the FECAVA lecture Cimetidine delivered at the 22nd EuroCongress in Vienna, Austria in June 2016. Eur J Comp An Pract Cimetidine, a histamine (H2) blocker often used to prevent (Winter 2016) 26(4); p9-p19. Go to http:// and treat gastrointestinal ulcers, is a potent inhibitor of www.ejcap.org for the interactive online presentation of this paper several families of cytochrome P450 enzymes in humans, including CYP2D6 and CYP3A4 [2]. Cimetidine can also inhibit transporter pumps and decrease the renal tubular Introduction secretion of some drugs [3]. Cimetidine decreases the clearance of many drugs to variable degrees in humans, In humans, the risk of adverse drug interactions multiplies including theophylline [4,5], lidocaine [6], midazolam [7,8], as the number of administered drugs increases.
    [Show full text]
  • Position Statement: Multi Dose Activated Charcoal
    Journal of Toxicology: Clinical Toxicology ISSN: 0731-3810 (Print) (Online) Journal homepage: http://www.tandfonline.com/loi/ictx19 Position Statement and Practice Guidelines on the Use of Multi-Dose Activated Charcoal in the Treatment of Acute Poisoning American Academy of Clinical Toxicology, European Association of Poisons Centres and Clinical Toxicologists To cite this article: American Academy of Clinical Toxicology, European Association of Poisons Centres and Clinical Toxicologists (1999) Position Statement and Practice Guidelines on the Use of Multi-Dose Activated Charcoal in the Treatment of Acute Poisoning, Journal of Toxicology: Clinical Toxicology, 37:6, 731-751, DOI: 10.1081/CLT-100102451 To link to this article: http://dx.doi.org/10.1081/CLT-100102451 Published online: 18 Nov 2004. Submit your article to this journal Article views: 389 View related articles Citing articles: 175 View citing articles Full Terms & Conditions of access and use can be found at http://www.tandfonline.com/action/journalInformation?journalCode=ictx19 Download by: [UPSTATE Medical University Health Sciences Library] Date: 29 May 2017, At: 09:34 Clinical Toxicology, 37(6), 731±751 (1999) Position Statement and Practice Guidelines on the Use of Multi-Dose Activated Charcoal in the Treatment of Acute Poisoning American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists ABSTRACT In preparing this Position Statement, all relevant scienti®c literature was identi- ®ed and reviewed critically by acknowledged experts using agreed criteria.1±124 Well-conducted clinical and experimental studies were given precedence over anecdotal case reports and abstracts were not usually considered. A draft Posi- tion Statement was then produced and subjected to detailed peer review by an international group of clinical toxicologists chosen by the American Academy of Clinical Toxicology and the European Association of Poisons Centres and Clinical Toxicologists.
    [Show full text]
  • Mad Honey Poisoning: a Review Rakesh Gami1* and Prajwal Dhakal2 1All Saints University, St
    linica f C l To o x l ic a o n r l o u g o y J Gami and Dhakal, J Clin Toxicol 2017, 7:1 Journal of Clinical Toxicology DOI: 10.4172/2161-0495.1000336 ISSN: 2161-0495 Review article Open Access Mad Honey Poisoning: A Review Rakesh Gami1* and Prajwal Dhakal2 1All Saints University, St. Vincent and The Grenadines 2Michigan State University, East Lansing, MI, USA *Corresponding author: Rakesh Gami, Assistant Professor, Department of Epidemiology, College of Medicine, All Saints University, St. Vincent and The Grenadines, Tel: +1-443-854-8522; E-mail: [email protected] Received date: January 01, 2017, Accepted date: January 19, 2017; Published date: January 20, 2017 Copyright: © 2017 Gami R, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Abstract Mad honey, which is different from normal commercial honey, is contaminated with grayanotoxins and causes intoxication. It is used as an alternative therapy for hypertension, peptic ulcer disease and is also being used more commonly for its aphrodisiac effects. Grayanotoxins, found in rhododendron plant, act on sodium ion channels and place them in partially open state. They also act on muscarinic receptors. Cardiac manifestations of mad honey poisoning include hypotension and rhythm disorders such as bradycardia, nodal rhythm, atrial fibrillation, complete atrioventricular block or even complete heart block. Additionally, patients may develop dizziness, nausea and vomiting, weakness, sweating, blurred vision, diplopia and impaired consciousness.
    [Show full text]
  • Caution from Using Cardiac Glycosides Digoxin Drug Which Have Properties Therapeutic Index
    Omran (2019): Use of cardiac glycosides digoxin November 2019 Vol. 22(8) Caution from using cardiac glycosides digoxin drug which have properties therapeutic index (Ti) narrow compare with the medications wide therapeutic index Salah Abd-Al kader Omran1* 1. Al-Muthanna University, college of Medicine, Iraq *Corresponding authorEmil: [email protected]. Phone: 009647705338787 Abstract Clinical research will be based on the practical application of randomly assigned patients over the age of 25 who numbered 730 at the Academic Teaching Hospital in Iraq - Samawa. We used drugs narrow therapeutic index (NTI), which is used with caution at a specific and calculated dose because it is life-threatening and has high toxicity. Compared to drugs that have wide therapeutic index (WTI) and less serious effects (such as aspirin, acetaminophen (paracetamol), penicillin, etc.), we selected acetaminophen (paracetamol) in patient research (a wide therapeutic index) and the dose and ratio between the toxic dose and the safe therapeutic dose of the drug, the research focuses on dilution To limit the risk of medication to patients (mortality), which is used as a measure of the relative safety of the drug in a particular drug treatment, our main work is limited to digoxin (cardiac glycosides) used in heart disease, discrimination with other drugs and knowledge, and in comparison to drugs. We used acetaminophen (paracetol) which is a broad indicator, so we based on previous knowledge in clinical pharmacy, dosage medications, therapeutic toxic dose, maximum dose, initial dose, maintenance dose, lethal dose, by knowing Therapeutic index for drug identification, therapeutic index, therapeutic ratio, TI can be calculated as a lethal dose of the drug by 50% of the population (LD50) divided by the minimum effective dose for 50% of the population (ED50), that is, TI = LD50 / ED50.
    [Show full text]
  • Medical Marijuana… Fact Versus Fiction
    MEDICAL MARIJUANA… FACT VERSUS FICTION Thomas F. Jan, DO, FAOCPMR Subspecialty Certified– Pain Medicine Diplomate – American Board of Addiction Medicine MASSAPEQUA PAIN MANAGEMENT AND REHABILITATION ADMINISTRATIVE DIRECTOR-CHRONIC PAIN MANAGEMENT 4200 SUNRISE HIGHWAY MATHER HOSPITAL-NORTHWELL HEALTH MASSAPEQUA, NY 11758 PORT JEFFERSON, NY 516-541-1064 THE I LOVE ME SLIDE: THOMAS F. JAN, DO, FAOCPMR, FKIA • 20 years private practice, board certified in pain medicine and addiction medicine • Current Chair, American Osteopathic Pain Medicine Conjoint Exam Committee • Administrative Director for Chronic Pain Management, John T. Mather Hospital, Port Jefferson, NY • Core faculty, PM&R residency program, Mercy Medical Center, Catholic Health System • Leadership Council, Long Island Council on Alcoholism and Drug Dependence (LICADD) • Medical Director, LICADD Opioid Overdose Prevention Program • Member, Nassau County, NY, County Executive's task force on Heroin and Prescription drug abuse • Former Medical Director, Town of Babylon Drug and Alcohol Program Disclosures: Speaker Bureau, US WorldMeds, Lucemyra OBJECTIVES A brief history of marijuana and its medical uses throughout history How does one get certified to prescribe medical marijuana Discussion about the endocannabinoid system (ECS) What receptors are there and what are they purported to do How do the various options affect the body through the ECS What are the risks involved and some discussion about the science MEDICAL MARIJUANA FOR OPIATE ADDICTION “I prescribed the cannabis simply
    [Show full text]